Cargando…

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients

In 2000, the Japanese Society for Parathyroid Intervention issued the ‘Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients’. Since then, the concept of ‘selective PEIT’ has been well accepted and the number of patients treated by this method i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onoda, Noritaka, Fukagawa, Masafumi, Tominaga, Yoshihiro, Kitaoka, Masafumi, Akizawa, Tadao, Koiwa, Fumihiko, Kakuta, Takatoshi, Kurokawa, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421126/ https://www.ncbi.nlm.nih.gov/pubmed/25983969 http://dx.doi.org/10.1093/ndtplus/sfn083

Ejemplares similares

Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention
por: Kakuta, Takatoshi, et al.
Publicado: (2008)

Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT—a single-centre trial
por: Tanaka, Reika, et al.
Publicado: (2008)

First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
por: Koiwa, Fumihiko, et al.
Publicado: (2022)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
por: Kakuta, Takatoshi, et al.
Publicado: (2020)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study
por: Kurita, Noriaki, et al.
Publicado: (2015)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
por: Kazama, Junichiro James, et al.
Publicado: (2022)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study
por: Hasegawa, Takeshi, et al.
Publicado: (2018)

Cellular changes following direct vitamin D injection into the uraemia-induced hyperplastic parathyroid gland
por: Shiizaki, Kazuhiro, et al.
Publicado: (2008)

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2020)

Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
por: Inaguma, Daijo, et al.
Publicado: (2023)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”
por: Akizawa, Tadao, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Medical management after parathyroid intervention
por: Tanaka, Motoko, et al.
Publicado: (2008)

Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
por: Goto, Shunsuke, et al.
Publicado: (2008)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan
por: Fukuma, Shingo, et al.
Publicado: (2013)

Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study
por: Fukuma, Shingo, et al.
Publicado: (2019)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism
por: Sato, Tetsuhiko, et al.
Publicado: (2019)

Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model
por: Yasuda, Atsushi, et al.
Publicado: (2019)

En Bloc Cadaver Kidney Transplantation From a 9-Month-Old Donor to an Adult Recipient: Maturation of Glomerular Size and Podocyte in the Recipient
por: Hirukawa, Takashi, et al.
Publicado: (2017)

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients
por: Kakuta, Takatoshi, et al.
Publicado: (2018)

A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro
por: Kawata, Takehisa, et al.
Publicado: (2018)

Indication and efficacy of PEIT in the management of secondary hyperparathyroidism
por: Koiwa, Fumihiko, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_e8bbt2cfdu2jn2a2qk4n6k044j